



Future Therapeutics Modalities for Acute Ischemic Stroke: Neuroprotective Agents, Intravascular Lysis, and More

William Barsan, MD
Professor, University of Michigan, USA

Learning Objectives

- Discuss the new therapeutic modalities for stroke treatment that are projected to be available in the next 5 years.
- Discuss the evidence available for the newest neuroprotectants on the horizon.
- Discuss the utility of other stroke therapies such as mechanical clot removers and hypothermia.

Background

It has been a decade since thrombolytics were introduced as the only therapeutic option for the treatment of ischemic stroke. Many new treatments have been tested and many have failed. The first generation of neuroprotectants had too many adverse effects or were not efficacious. However, since then new neuroprotectants are in clinical trials with much better adverse effects profiles. Clinical efficacy remains to be seen. Other modalities, such as hypothermia and mechanical clot removers, have shown considerable promise.

Dr. Barsan will discuss the latest evidence for the new generation of neuroprotectants. In addition, he will look at some of the evidence for other new therapeutic modalities. Lastly, he will discuss what stroke therapy may be like in five to ten years when multiple therapeutic modalities may exist and choices between them may be necessary.

Key Clinical Questions

- What neuroprotectants are being studied and might be available for use in the next few years?
- What other therapeutic modalities are being studied that may be efficacious in treating stroke?
- Will new therapies be combined with thrombolytics to improve outcome or extend the window for therapy?